Phase 3Completed
Efficacy and Safety Study of the HS-25 Combination With Atorvastatin in Subjects With Hypercholesterolemia in Coronary Heart Diseases (HS-25-III-02)
Randomized,Double Blind,Double Dummy, Multi-center Study of Efficacy and Safety of HS-25 Combination With Atorvastatin in Subjects With Hypercholesterolemia in Coronary Heart Diseases
- Sponsor
- Zhejiang Hisun Pharmaceutical Co. Ltd. (Industry)
- Enrolment
- 255 enrolled
- Conditions
- Hypercholesterolemia in Coronaory Heart Disease
- Interventions
- HS-25 and Atorvastatin; Atorvastatin
- Ages
- adults, older adults
- Registry
- NCT03433196
Full record on ClinicalTrials.gov
From the registry
To determine the efficacy of HS-25 (20mg) in reducing low density lipoprotein-cholesterol (LDL-C) levels after a 12-week period of treatment in combination with Atorvastatin in subjects with hypercholesterolemia and coronary heart diseases; To determine the safety of HS-25 (20mg) combination with Atorvastatin in subjects with hypercholesterolemia and coronary heart diseases
Primary outcomes
- Percent change of LDL-C
History
Last registry update
Study completion
Primary completion
Registered
Started